EGFR and triple-negative breast carcinoma: Furthermore, an aptamer that targets an epidermal growth factor receptor (EGFR)–integrin αvβ3 complex was shown to impair αvβ3-dependent adhesion, as well as the matrix-induced interaction of the integrin with EGFR, thereby inhibiting growth and vasculogenic mimicry of triple-negative breast cancer cells117.